Exchange: NASDAQ·Updated 07:30 PM EDT

MGTX News

News
all
press releases
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial...
PR Newswire
More News
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia PR Newswire NEW YORK, Aug. 11, 2026 Graviton...
PR Newswire
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
Pacira (PCRX) delivered earnings and revenue surprises of +14.06% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
MeiraGTx Enters $400 Mln Investment Deal With Oberland Capital
(RTTNews) - MeiraGTx Holdings plc (MGTX), a clinical-stage genetic medicine company, on Tuesday entered into an agreement with Oberland Capital Management for an investment of up to $400 million...
Nasdaq News: Markets

Advertisement|Remove ads.